Publications by authors named "Karin Rerat"

Claim this Profile
R
Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
Ayman Tourbah, Caroline Papeix, Patricia Tourniaire, Karin Rerat, Mohamed Meite

Mult Scler Relat Disord· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anxiety and Coping Strategy Changes in Multiple Sclerosis Patients Initiating Fingolimod: The GRACE Prospective Study.
Thibault Moreau, Catherine Bungener, Olivier Heinzlef, Laurent Suchet, Florent Borgel, Karin Rerat

Eur Neurol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
Elizabeth Berry-Kravis, Vincent Des Portes, Randi Hagerman, Sébastien Jacquemont, Perrine Charles, Karin Rerat

Sci Transl Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France.
Erin Johansson, Anders Gustavsson, Carolin Miltenburger, Korinna Karampampa, Lucien Rumbach

Mult Scler· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
Alain Destée, Karin Rérat, Isabelle Bourdeix

Eur Neurol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis